MUMBAI, India, Oct. 5 -- Intellectual Property India has published a patent application (202621098998 A) filed by Dr. Rupali Rajesh Tasgaonkar; Dr. Babita Himmatrao More; and Dr. Puja Gulabrao Vyawhare on August 16, 2026, for Development Of Multifunctional Nanoemulsion System For Improved Solubility, Stability And Pharmacological Performance Of Novel Drug Candidates.
Inventors include Dr. Rupali Rajesh Tasgaonkar; Dr. Babita Himmatrao More; and Dr. Puja Gulabrao Vyawhare.
The application for the patent was published on October 02, 2026, under issue no. 40/2026.
Abstract: The present invention relates to a multifunctional nanoemulsion system for improving solubility, stability, dissolution and pharmacological performance of novel drug candidates, particularly poorly water-soluble and/or unstable active pharmaceutical ingredients. The nanoemulsion comprises an active pharmaceutical ingredient, an oil phase, an aqueous phase, at least one surfactant and at least one co-surfactant, with optional pharmaceutically acceptable functional excipients including antioxidants, stabilizers, buffering agents, preservatives, penetration enhancers and release modifiers. The components are selected and proportioned to provide a substantially stable nanoscale dispersed system capable of maintaining the drug candidate in a solubilized, dispersed or interfacially associated state. The formulation provides increased interfacial surface area, improved apparent aqueous solubility, enhanced dissolution and reduced precipitation, while providing a protective environment for improving physical and chemical stability of the active pharmaceutical ingredient. The nanoemulsion may be prepared using high-energy or low-energy emulsification techniques and optimized based on droplet size, polydispersity, surface characteristics, drug content, incorporation efficiency, dilution stability and storage stability. The resulting formulation may be adapted for oral, topical, transdermal, mucosal or other pharmaceutically acceptable routes of administration and may provide improved absorption, bioavailability and pharmacological response compared with an unformulated drug candidate. The invention therefore provides a versatile and scalable pharmaceutical formulation platform for overcoming solubility and stability limitations encountered during development of novel drug candidates. Accompanied Drawing [FIGS. 1-2]
Disclaimer: Curated by HT Syndication.
